Jenburkt Pharmaceuticals working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

48.77×	48.38×	46.84×	42.93×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.80×	0.84×	0.93×	0.96×
0.76×	0.87×	0.31×	0.69×
0.66×	0.75×	0.27×	0.61×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

JENBURPH₹872.30

Jenburkt Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersBPLPHARMA KPL MAKERSL NOVARTIND PARNAXLAB SGRL SHUKRAPHAR SUNLOC

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
Receivable Days (DSO)	42.93	46.84	48.38	48.77
Asset Turnover	0.96	0.93	0.84	0.80
Cash Conversion (CFO/Net Income)	0.69	0.31	0.87	0.76
CFO/EBITDA	0.61	0.27	0.75	0.66

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.